Skip to main content
SpringerLink
Log in

Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma

  • Original Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Objectives

The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma.

Materials and methods

Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m2 for 5 days, carboplatin 400 mg/m2 for 2 days, and etoposide 100 mg/m2 for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 μg kg−1 day−1.

Results

After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 × 106 cells/kg (range, 0.2 to 71.2 × 106 cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed.

Conclusions

These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21:1581–1591

    Article  PubMed  CAS  Google Scholar 

  2. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832–845

    PubMed  CAS  Google Scholar 

  3. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 17:2127–2136

    PubMed  CAS  Google Scholar 

  4. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS (2005) Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41:727–734

    Article  PubMed  CAS  Google Scholar 

  5. Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675

    Article  PubMed  Google Scholar 

  6. Gardner SL (2004) Application of stem cell transplant for brain tumors. Pediatr Transplant 8(Suppl 5):28–32

    Article  PubMed  Google Scholar 

  7. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 14(Suppl 1):i5–i10

    Article  PubMed  Google Scholar 

  8. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 17:3776–3785

    PubMed  CAS  Google Scholar 

  9. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS (2002) Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 13:460–469

    Article  PubMed  CAS  Google Scholar 

  10. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS (2005) Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 44:338–347

    Article  PubMed  Google Scholar 

  11. López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Diaz F, Valdes-Sanchez M, Delgado-Huerta S, Wanzke-del Angel V, Ramon-Garcia G, Rodriguez-Jimenez H, Hernandez-Contreras I, Santacruz-Castillo E, Romo-Rubio HA (2003) Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. Childs Nerv Syst 19:818–823

    Article  PubMed  Google Scholar 

  12. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer 32A:2229–2235

    Article  PubMed  CAS  Google Scholar 

  13. Loss JF, Santos PP, Leone LD, Brunetto AL (2004) Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 42:139–144

    Article  PubMed  Google Scholar 

  14. Kung FH, Desai SJ, Dickerman JD, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S (1995) Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 17:265–269

    Article  PubMed  CAS  Google Scholar 

  15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  16. Fruehauf S, Seggewiss R (2003) It’s moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 122:360–375

    Article  PubMed  CAS  Google Scholar 

  17. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18:1360–1377

    PubMed  CAS  Google Scholar 

  18. Sezer O, Possinger K, Metzner B, Illiger HJ, Wattad M, Heit W, Fuss H, Schultze W (2000) Optimal CD34 (+) cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol 18:3319–3320

    PubMed  CAS  Google Scholar 

  19. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD (1990) Carboplatin in childhood brain tumors. A Children’s Cancer Study Group Phase II trial. Cancer 66:2465–2469

    Article  PubMed  CAS  Google Scholar 

  20. Mastrangelo R, Lasorella A, Riccardi R, Colosimo C, Iavarone A, Tornesello A, Mastrangelo S, Ausili-Cefaro G, Di Rocco C (1995) Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an “up-front” study. Med Pediatr Oncol 24:188–196

    Article  PubMed  CAS  Google Scholar 

  21. Boor R, Huber A, Gutjahr P (1994) Etoposide treatment in recurrent medulloblastoma. Neuropediatrics 25:39–41

    Article  PubMed  CAS  Google Scholar 

  22. Kobrinsky NL, Packer RJ, Boyett JM, Stanley P, Shiminski-Maher T, Allen JC, Garvin JH (1999) Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children’s Cancer Group study, CCG-9881. J Neurooncol 45:47–54

    Article  PubMed  CAS  Google Scholar 

  23. Chastagner P, Sommelet-Olive D, Kalifa C, Brunat-Mentigny M, Zucker JM, Demeocq F, Baranzelli MC, Tron P, Bergeron C, Pein F (1993) Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 21:49–53

    Article  PubMed  CAS  Google Scholar 

  24. Heideman RL, Kovnar EH, Kellie SJ, Douglass EC, Gajjar AJ, Walter AW, Langston JA, Jenkins JJ, Li Y, Greenwald C (1995) Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13:2247–2254

    PubMed  CAS  Google Scholar 

  25. López-Aguilar E, Sepúlveda-Vildósola AC, Rivera-Márquez H, Cerecedo-Diaz F, Santacruz-Castillo E, Valdez-Sanchez M, Arias-Gomez J, Quintana-Roldan G (1998) Survival of patients with medulloblastoma treated with carboplatin and etoposide before and after radiotherapy. Arch Med Res 29:313–317

    PubMed  Google Scholar 

  26. Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys 46:269–279

    Article  PubMed  CAS  Google Scholar 

  27. Kühl J, Müller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, Graf N, Gnekow A, Scheurlen W, Gobel U, Wolff JE, Bamberg M, Kaatsch P, Kleihues P, Rating D, Sorensen N, Wiestler OD (1998) Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT’88/’89. Klin Pädiatr 210:227–233

    PubMed  Google Scholar 

  28. Gajjar A, Kühl J, Epelman S, Bailey C, Allen J (1999) Chemotherapy of medulloblastoma. Childs Nerv Syst 15:554–562

    Article  PubMed  CAS  Google Scholar 

  29. Gerke P, Filejski W, Robins HI, Wiedemann GJ, Steinhoff J (2000) Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. J Cancer Res Clin Oncol 126:173–177

    Article  PubMed  CAS  Google Scholar 

  30. Skinner R (2003) Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 41:190–197

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu, 431-3192, Japan

    Shuichi Okada, Teruaki Hongo, Kimiyoshi Sakaguchi & Takehiko Ohzeki

  2. Department of Radiology, Hamamatsu University School of Medicine, Hamamatsu, Japan

    Kazunori Suzuki

  3. Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Japan

    Shigeru Nishizawa

Authors
  1. Shuichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruaki Hongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kimiyoshi Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunori Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shigeru Nishizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takehiko Ohzeki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuichi Okada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okada, S., Hongo, T., Sakaguchi, K. et al. Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma. Childs Nerv Syst 23, 407–413 (2007). https://doi.org/10.1007/s00381-006-0282-5

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-006-0282-5

Keywords

Search

Navigation